



Copy numbers count for autism
Among the elusive genetic causes for autism, copy number variations are 
emerging as an important factor. Testing for these might help parents determine 
the risk of recurrence. Michael Gross reports.However, this still leaves space for 
genetic causes, and even some of the 
non-inherited cases may arise from 
Mind image: Autism is characterized by a 
triad of impairments to social behaviour, 
communication and imagination. One school 
of thought claims that individuals with autism 
lack a ‘theory of mind’, implying that they 
don’t have a concept of themselves and other 
people as distinct, thinking personalities 
with their own beliefs, desires, etc. (Photo: 
N.H. Gross.)Autism, a neurodevelopmental 
disorder defined by the triad of 
impairments affecting social behaviour, 
communication, and imagination, 
has apparently become tenfold more 
prevalent in the last four decades 
(Curr. Biol. (2002), 12, R42). There is 
clear evidence for genetic causation 
but, of the around 80 genes that have 
been linked to autism or to the more 
widely defined autistic spectrum 
disorders (ASDs), none accounts for 
a large proportion of cases, and none 
has a clearly established causation 
mechanism as yet. Only in the relatively 
rare cases where autism is a side effect 
of a chromosomal aberration, such as 
fragile X syndrome, can the causes be 
pinned down with some certainty (J.C. 
Darnell et al. Cell (2011), 146, 247–261). 
Since 2007, several studies have 
found evidence suggesting that rare 
copy number variations (CNVs) are 
linked to ASDs. Genome sequencing 
has shown that CNVs, typically 
involving the duplication or deletion of 
more than 1,000 DNA nucleotides, are 
quite common in the human genome, 
and those that are widespread in 
the population are believed to be 
harmless, although genome studies of 
cancer cells have also detected CNVs 
that are under suspicion of causing 
or helping the cancer. Researchers 
have estimated that the genomes 
of any two unrelated people will 
differ with respect to copy number in 
around 0.4% of the total number of 
nucleotides. 
In 2010, the Autism Genome Project 
Consortium reported that in a sample 
of nearly 1,000 people with ASDs, 
compared with a group of matched 
controls, there was a significantly 
higher burden of rare CNVs involving 
functional genes. The researchers 
conclude that CNVs are likely to play a 
role in causing autism and other ASDs 
(Nature (2010), 466, 368–372). 
Simplex families, complex relations
Three recent papers published back-
to-back in Neuron have confirmed 
this conclusion and fleshed it out with additional insights. Two research 
groups used the Simons Simplex 
Collection, a collective of more than 
1,000 families, each including exactly 
one member with a diagnosis on the 
autistic spectrum, to look for rare 
CNVs and particularly for those that 
occur in the patient for the first time 
(de novo) as opposed to inherited 
variations. 
Stephan J. Sanders et al. (Neuron 
(2011), 70, 863–885) and Dan Levy 
et al. (Neuron (2011),  70, 886–897)  
both report a significant excess of 
rare de novo CNVs in the ASD patients 
(the probands) compared with their 
unaffected siblings. While these occur 
in many different areas of the genome, 
the studies have identified six areas 
that show a statistically significant link 
with ASDs. 
Among these, the area 16p11.2 
is the only one that is linked to 
more than 1% of the cases studied. 
Therefore it has emerged as a 
promising candidate for further in-
depth studies, as it should be possible 
to find more patients with variations at 
this site. 
A second site that holds promise for 
further research is 7q11.23. Deletions 
of this region are known to cause 
Williams syndrome, the symptoms 
of which include hypersociable 
behaviour. It is tantalising that deletion 
and duplication of this stretch of 
DNA are linked to the symmetrically 
opposite effect on social behaviour 
seen in Williams syndrome and ASDs. 
This observation clearly opens up 
opportunities for biochemical and 
animal studies into the mechanistic 
link between gene dosage and 
behaviour. 
The two studies disagree on the role 
of inherited CNVs (which, however, 
were deliberately deselected by 
the study design, which excludes 
families with multiple cases of ASDs). 
Sanders et al. report that they see no 
statistically significant link of inherited 
CNVs with ASDs, while Levy et al. say 
that in some rare cases they can spot 
such a link. Detailed investigation of inherited CNVs and of their relative 
importance compared with de novo 
CNVs would require similar research 
with a group of families with several 
probands per family. 
While it has not yet been calibrated 
for comparison with inherited 
variations, the surprisingly strong 
significance of de novo CNVs is 
compatible with a new genetic study 
that suggests the heritability of 
ASDs is much lower than presumed 
so far. Joachim Hallmayer et al. 
(Arch. Gen. Psychiatry DOI: 10.1001/
archgenpsychiatry.2011.76) give the 
heritability of autism as 37% (with a 
95% confidence interval ranging from 
8 to 84%), and for ASD 38% (14–67%). 
Geneticist Richard Holt from the 
Wellcome Trust Centre for Human 
Genetics at Oxford comments on 
this finding: “This is an important 
study, especially given its size and 
the method of ascertainment of 
individuals with autism or ASD. While 
it should be viewed in the light of 
previous twin studies, if we accept 
the numbers from this study alone the 
significant decrease in the estimated 
genetic component may help 
explain the difficulties experienced 
in identifying the genes underlying 
autism.” 
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Labelled autistic: Temple Grandin, one of the first generation of children to be diagnosed 
with autism, managed to build a successful career in animal science partly by using her own 
unusual sensitivity and anxieties to better understand animals. She is the author of a widely 
known memoir (Emergence: Labeled Autistic) and the subject of a recent HBO film in which the 
actor Claire Danes impersonates her. (Photo: Jonathan D. Thoreson.)de novo change to genes, such as the 
CNVs. Holt concludes that “the study 
by Hallmayer et al. itself still points to 
a sizeable genetic contribution, and 
over the last decade the search for 
genetic factors for autism has met 
with significant success. Given their 
variance from previous studies, it will 
be interesting to see if these estimates 
are replicated in future work.”
Girls’ and boys’ networks
One other important question on 
which the two recent CNV studies diverge is the gender asymmetry. 
Autism and ASDs affect many more 
boys than girls, and simple genetic 
explanations such as recessive genes 
on the X chromosome (which explains 
the asymmetry in haemophilia) have 
been ruled out. Sanders et al. say 
they can derive no explanation of 
the gender imbalance from their 
results, while Levy et al. conclude that 
their results are in agreement with 
the hypothesis that girls are more 
resistant against the effects of a given 
genetic burden. This conclusion is supported by 
the results of a group from Columbia 
University (New York), who developed 
a new analysis tool called NETBAG 
(network-based analysis of genetic 
associations) and applied it to the 
CNV results of Levy et al. Essentially, 
the authors constructed a network of 
genes where a connection between 
two genes represents the likelihood 
that these genes contribute to similar 
phenotypes. Locating the genes 
affected by significant CNVs in the 
study of Levy et al. in this network, 
the authors identified clusters of 
functionally related genes that are 
perturbed by de novo CNVs in some 
of the probands. 
The analysis of these clusters 
revealed that many of the processes 
likely to be perturbed by the CNVs 
identified by Levy et al. are linked to 
“the development and maturation 
of synaptic contacts in the brain,” 
the authors write. Specifically, their 
analysis links adhesive proteins like 
neurexin and neuroligin, complex 
structures like the postsynaptic 
density, and processes like axon 
guidance and neuron motility to ASDs. 
The NETBAG analysis supports the 
hypothesis, the authors summarise, 
“that perturbed synaptogenesis is at 
the heart of autism.” 
On the gender issue, the data from 
Levy et al. suggest that the CNVs 
found in female probands are affecting 
a larger number of genes than in 
males. In addition to this, the network 
analysis indicates that the genes 
affected in female probands are more 
important for the functional network 
in which they are involved than those 
found affected in males. Both findings 
are consistent with the hypothesis that 
it takes a stronger genetic disruption 
to produce the autistic phenotype in 
females than in males. 
Once more, additional research 
targeted specifically at the new 
candidate genes and their functional 
context will be necessary to confirm 
and flesh out these suggestions. 
Testing times 
The realisation that CNVs and de novo 
CNVs in particular play a significant 
role in autism raises the question 
of whether it would be useful to 
test patients for these variations. 
Yiping Shen et al. (Pediatrics (2010) 
125, e727) have recently reported a 
detailed comparison of chromosome 
microarray (CMA) testing for CNVs 
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Counting copies: Large sections of DNA, 
which may contain one or several genes, are 
often found duplicated in the human genome. 
These so called copy number variations are 
as important for human genetic diversity 
as point mutations and have recently been 
implicated in medical conditions including 
autism. (Photo: M. Gross.)
Brown algae
Quick guide(also known as array genomic 
comparative hybridization, or  
array CGH) with established 
diagnostic procedures including 
G-banded karyotype and fragile X 
testing. 
Arrays for CMA tests are widely 
available, but have not yet entered 
general practice to the extent that 
generally agreed standards and 
references exist. Applying CMA 
to the entire genomes of 697 ASD 
patients, Shen et al. detected clinically 
relevant CNVs in 51 individuals (7.3%). 
Targeting the method at the most 
promising genomic regions with a 
smaller group of patients, they only 
had a discovery rate of 5.3%, but in 
both cases the yields are much higher 
than for established chromosomal 
tests. 
These authors conclude that “CMA 
had the highest detection rate among 
clinically available genetic tests 
for patients with ASD”. Therefore, 
they recommend, “CMA should 
be considered as part of the initial 
diagnostic evaluation of patients with 
ASD”. The International Standard 
Cytogenomic Array (ISCA) consortium 
conducted a literature review and 
came to the same conclusion (Am. J. 
Hum. Genet. (2010) 86, 749). 
Still, the analysis by Shen et al. 
detected clinically relevant CNVs in only 7.3% of the ASD patients tested, 
and the specific significance of those 
found remains uncertain. As none 
of the diagnostic results suggests 
any treatment options, there is no 
immediate benefit to the patients. 
They may benefit indirectly in the long 
term, as more data accumulate and 
scientists gain a better understanding. 
Patients’ families may benefit from 
finding out whether the specific case 
is associated with a de novo event 
or an inherited variation, which can 
drastically change the recurrence risk 
for future offspring of both the parents 
and unaffected siblings. 
Clinical testing may in the long term 
also help to clarify the boundaries of 
the autistic spectrum and get a more 
reliable measure of its prevalence. 
An indication regarding the extent to 
which these issues are still in flow 
has emerged recently with a study 
conducted in South Korea which 
claimed a surprisingly high prevalence 
of ASD of 2.64% (3.74% for boys and 
1.47% for girls), based on a screening 
of over 55,000 children aged 7 to 12 
(Am. J. Psychiatry, doi: 10.1176/appi.
ajp.2011.10101532).
Young Shin Kim and co-workers at 
Yale went through a case identification 
process involving several steps and 
addressing the entire population of 
7- to 12-year-olds in the community 
they studied. An initial screening 
covering both regular schools and 
special-needs schools yielded around 
2,000 potential candidates, of whom 
286 were assessed for ASD. Of these 
assessments, 201 returned a positive 
diagnosis for ASD. As there were 
inevitable losses along the way of 
families who didn’t respond or failed 
to consent to the assessment, the 
authors have had to use statistical 
extrapolation to arrive at the reported 
prevalence rates. 
Beyond statistical uncertainties, 
these findings raise all kinds of 
questions as to where to draw the 
line between ASD and ‘normal’, 
whether the condition is still widely 
underdiagnosed, and whether 
prevalence is still increasing.  
Nearly seventy years after  
Leo Kanner first recognised and 
described autism, its scientific 
understanding is still very much  
at the beginning.  
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
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What are brown algae? Brown 
algae or brown seaweeds are the 
dominant organisms in many of 
the world’s coastal regions, where 
they are responsible for the bulk of 
primary production, often forming 
extensive undersea forests that host 
a high level of biodiversity. From an 
evolutionary point of view, brown algae 
are members of the stramenopiles 
(or heterokonts), a group that has 
been evolving independently of the 
well-studied animal, fungal and green 
plant lineages for over a billion years. 
As a result of this unique evolutionary 
history, these organisms exhibit 
many novel features. For example, 
they represent one of a very limited 
number of eukaryotic groups that 
have independently evolved complex 
multicellularity. Brown algae also exhibit 
some remarkable characteristics in 
terms of their cell biology; cytokinesis, 
for example, having features typical of 
both animals (centrosomes) and green 
plants (centrifugal cell plate formation). 
Moreover, since their divergence 
from other eukaryotic groups, brown 
algae have evolved several innovative 
metabolic processes, making them 
highly interesting targets for the 
discovery of novel biomolecules for 
industrial use. There is also increasing 
interest in the use of brown algae as a 
source of biomass for fuel production 
due to their very rapid growth rates 
and the fact that cultivation does not 
compete with food crops for the use of 
arable land. The giant kelp Macrocystis 
pyrifera, for example, is one of the 
largest and most rapidly growing 
organisms on the planet, reaching 
lengths of up to 60 metres. 
Has a model organism been developed 
to study all these interesting aspects 
of brown algal biology? Yes, the small, 
filamentous brown alga Ectocarpus 
was proposed as a model organism 
for the brown algae about seven years 
ago and a number of genetic and 
molecular tools have been developed 
for this organism. Available tools 
include a considerable amount of 
cDNA and small RNA sequence data, 
